Sigma Planning Corp Boosts Position in iShares Biotechnology ETF $IBB

Sigma Planning Corp grew its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 60.1% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 10,031 shares of the financial services provider’s stock after purchasing an additional 3,766 shares during the period. Sigma Planning Corp’s holdings in iShares Biotechnology ETF were worth $1,694,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Basepoint Wealth LLC acquired a new position in iShares Biotechnology ETF in the fourth quarter valued at $26,000. Cary Street Partners Financial LLC acquired a new stake in shares of iShares Biotechnology ETF during the fourth quarter worth about $29,000. Darwin Wealth Management LLC purchased a new stake in shares of iShares Biotechnology ETF in the 2nd quarter valued at about $25,000. Caitlin John LLC acquired a new stake in shares of iShares Biotechnology ETF in the fourth quarter valued at approximately $34,000. Finally, Cornerstone Planning Group LLC acquired a new stake in iShares Biotechnology ETF during the 4th quarter worth $35,000. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Performance

Shares of IBB stock opened at $189.76 on Friday. iShares Biotechnology ETF has a 52-week low of $128.84 and a 52-week high of $199.05. The stock’s 50-day moving average price is $177.79 and its 200 day moving average price is $173.40.

iShares Biotechnology ETF Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 18th. Stockholders of record on Monday, June 15th were paid a dividend of $0.0238 per share. This represents a $0.10 dividend on an annualized basis and a dividend yield of 0.1%. The ex-dividend date was Monday, June 15th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.